

NON-GAAP RECONCILIATION AND SUPPLEMENTAL DATA

STATEMENT OF OPERATIONS

Anika Therapeutics, Inc. and Subsidiaries
 Consolidated Statements of Operations
 (in thousands, except per share data)
 (unaudited)

	For the Three Months Ended March 31,		For the Three Months Ended March 31,	
	2026	2025	2026	2025
Revenue	\$ 29,612	\$ 26,168	\$ 29,612	\$ 26,168
Cost of Revenue	10,615	11,487	10,615	11,487
Gross Profit	18,997	14,681	18,997	14,681
Operating expenses:				
Research and development	6,713	6,059	6,713	6,059
Selling, general and administrative	17,772	12,906	17,772	12,906
Total operating expenses	24,485	18,965	24,485	18,965
Loss from operations	(5,488)	(4,284)	(5,488)	(4,284)
Interest and other income (expense), net	667	415	667	415
Loss before income taxes	(4,821)	(3,869)	(4,821)	(3,869)
Provision for income taxes	235	89	235	89
Loss from continuing operations	(5,056)	(3,958)	(5,056)	(3,958)
Loss from discontinued operations, net of tax	-	(915)	-	(915)
Net loss	\$ (5,056)	\$ (4,873)	\$ (5,056)	\$ (4,873)
Net loss per share:				
Basic				
Continuing Operations	\$ (0.37)	\$ (0.28)	\$ (0.37)	\$ (0.28)
Discontinued Operations	\$ -	\$ (0.06)	\$ -	\$ (0.06)
	\$ (0.37)	\$ (0.34)	\$ (0.37)	\$ (0.34)
Diluted				
Continuing Operations	\$ (0.37)	\$ (0.28)	\$ (0.37)	\$ (0.28)
Discontinued Operations	\$ -	\$ (0.06)	\$ -	\$ (0.06)
	\$ (0.37)	\$ (0.34)	\$ (0.37)	\$ (0.34)
Weighted average common shares outstanding:				
Basic	13,531	14,297	13,531	14,297
Diluted	13,531	14,297	13,531	14,297

BALANCE SHEET

Anika Therapeutics, Inc. and Subsidiaries
 Consolidated Balance Sheets
 (in thousands, except per share data)
 (unaudited)

ASSETS	March 31, 2026	December 31, 2025
Current assets:		
Cash and cash equivalents	\$ 41,020	\$ 57,481
Accounts receivable, net	25,768	23,690
Inventories, net	22,838	18,787
Prepaid expenses and other current assets	3,935	3,400
Total current assets	<u>93,561</u>	<u>103,358</u>
Property and equipment, net	39,722	40,324
Right-of-use assets	25,430	25,939
Other long-term assets	4,303	4,034
Notes receivable	5,679	5,636
Deferred tax assets	1,150	1,275
Intangible assets, net	1,650	1,650
Goodwill	7,892	8,054
Total assets	<u>\$ 179,387</u>	<u>\$ 190,270</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 6,339	\$ 6,041
Accrued expenses and other current liabilities	14,627	15,867
Total current liabilities	<u>20,966</u>	<u>21,908</u>
Other long-term liabilities	726	701
Lease liabilities	23,794	24,196
Stockholders' equity:		
Common stock, \$0.01 par value	133	139
Additional paid-in-capital	83,347	87,498
Accumulated other comprehensive loss	(5,310)	(4,959)
Retained earnings	55,731	60,787
Total stockholders' equity	<u>133,901</u>	<u>143,465</u>
Total liabilities and stockholders' equity	<u>\$ 179,387</u>	<u>\$ 190,270</u>

CASH FLOW STATEMENT

Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

	For the Three Months Ended March 31,	
	2026	2025
Cash flows from operating activities:		
Net loss	\$ (5,056)	\$ (4,873)
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	1,407	1,383
Amortization of acquisition related intangible assets	-	209
Non-cash operating lease cost	464	577
Stock-based compensation expense	6,641	2,863
Deferred income taxes	108	18
Provision for doubtful accounts	(24)	(346)
Provision for inventory	1,032	832
Interest income on notes receivable	(179)	(224)
Gain on sale of assets	(52)	(300)
Changes in operating assets and liabilities:		
Accounts receivable	(2,180)	3,034
Inventories	(5,407)	523
Prepaid expenses, other current and long-term assets	(1,728)	(203)
Accounts payable	745	47
Operating lease liabilities	(468)	(569)
Accrued expenses, other current and long-term liabilities	(1,339)	(3,088)
Income taxes	1,190	(13)
Net cash provided by operating activities	<u>(4,846)</u>	<u>(130)</u>
Cash flows from investing activities:		
Purchases of property and equipment	(1,431)	(2,824)
Proceeds from sale of Parcus	-	4,496
Note receivable	192	-
Net cash used in investing activities	<u>(1,239)</u>	<u>1,672</u>
Cash flows from financing activities:		
Repurchases of common stock	(8,690)	(3,971)
Cash paid for tax withheld on vested restricted stock awards	(1,657)	(1,467)
Net cash used in financing activities	<u>(10,347)</u>	<u>(5,438)</u>
Exchange rate impact on cash	<u>(29)</u>	<u>108</u>
Increase (decrease) in cash and cash equivalents	(16,461)	(3,788)
Cash and cash equivalents at beginning of period	57,481	57,159
Cash and cash equivalents at end of period	<u>\$ 41,020</u>	<u>\$ 53,371</u>

RECONCILIATION TABLES – GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA

Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Income (Loss) from Continued Operations to Adjusted EBITDA
 (in thousands)
 (unaudited)

	For the Three Months Ended March 31,		For the Years Ended March 31,	
	2026	2025	2026	2025
Loss from continuing operations	\$ (5,056)	\$ (3,958)	\$ (5,056)	\$ (3,958)
Interest and other (income) expense, net	(667)	(415)	(667)	(415)
Provision for income taxes	235	89	235	89
Depreciation and amortization	1,407	1,416	1,407	1,416
Stock-based compensation	6,641	2,995	6,641	2,995
Non-recurring professional fees	169	-	169	-
Severance costs	1,587	-	1,587	-
Adjusted EBITDA	<u>\$ 4,316</u>	<u>\$ 127</u>	<u>\$ 4,316</u>	<u>\$ 127</u>

RECONCILIATION TABLES – GAAP NET INCOME TO ADJUSTED NET INCOME

Anika Therapeutics, Inc. and Subsidiaries
 Reconciliation of GAAP Net Income from Continuing Operations to Adjusted Net Income from Continuing Operations
 (in thousands)
 (unaudited)

	For the Three Months Ended March 31,		For the Years Ended March 31,	
	2026	2025	2026	2025
Loss from continuing operations	\$ (5,056)	\$ (3,958)	\$ (5,056)	\$ (3,958)
Product rationalization, tax effected	-	-	-	-
Arbitration settlement, tax effected	-	-	-	-
Stock-based compensation, tax effected	6,965	3,063	6,965	3,063
Non-recurring professional fees, tax effected	177	-	177	-
Severance costs, tax effected	1,664	-	1,664	-
Adjusted net income (loss) from continuing operations	<u>\$ 3,750</u>	<u>\$ (895)</u>	<u>\$ 3,750</u>	<u>\$ (895)</u>

RECONCILIATION TABLES – GAAP EPS TO ADJUSTED EPS

Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Diluted Earnings from Continuing Operations Per Share to Adjusted Diluted Earnings from Continuing Operations Per Share
(in thousands, except per share data)
(unaudited)

	For the Three Months Ended March 31,		For the Years Ended March 31,	
	2026	2025	2026	2025
Diluted loss from continuing operations per share	\$ (0.37)	\$ (0.28)	\$ (0.37)	\$ (0.28)
Stock-based compensation, tax effected	0.51	0.22	\$ 0.51	0.22
Non-recurring professional fees, tax effected	0.01	-	\$ 0.01	-
Severance costs, tax effected	0.12	-	0.12	-
Costs of shareholder activism, tax effected	-	-	-	-
Adjusted diluted net income (loss) from continuing operations per share	<u>\$ 0.27</u>	<u>\$ (0.06)</u>	<u>\$ 0.27</u>	<u>\$ (0.06)</u>

REVENUE BY CHANNEL

Anika Therapeutics, Inc. and Subsidiaries
Revenue by Product Family
 (in thousands, except percentages)
 (unaudited)

	For the Three Months Ended March 31,				For the Three Months Ended March 31,			
	2026	2025	\$ change	% change	2026	2025	\$ change	% change
OEM Channel	\$ 17,035	\$ 14,909	\$ 2,126	14%	\$ 17,035	\$ 14,909	\$ 2,126	14%
Commercial Channel	12,577	11,259	1,318	12%	12,577	11,259	1,318	12%
	<u>\$ 29,612</u>	<u>\$ 26,168</u>	<u>\$ 3,444</u>	<u>13%</u>	<u>\$ 29,612</u>	<u>\$ 26,168</u>	<u>\$ 3,444</u>	<u>13%</u>

